{"id":"NCT00272792","sponsor":"BioMarin Pharmaceutical","briefTitle":"Study of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet","officialTitle":"A Phase 3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin to Increase Phenylalanine Tolerance in Phenylketonuric Children on a Phenylalanine-restricted Diet","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-02","primaryCompletion":null,"completion":"2006-11","firstPosted":"2006-01-09","resultsPosted":"2009-07-09","lastUpdate":"2015-08-13"},"enrollment":45,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Phenylketonurias"],"interventions":[{"type":"DRUG","name":"Sapropterin Dihydrochloride","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Sapropterin Dihydrochloride","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this trial is to evaluate the ability of Phenoptin to increase phenylalanine (phe) tolerance in children with phenylketonuria who are following a phe-restricted diet.","primaryOutcome":{"measure":"Amount of Dietary Supplemented Phenylalanine (Phe)Tolerated in Children With Phenylketonuria","timeFrame":"at Week 10","effectByArm":[{"arm":"Sapropterin Dihydrochloride","deltaMin":20.9,"sd":15.4},{"arm":"Placebo","deltaMin":2.9,"sd":4}],"pValues":[{"comp":"OG000","p":"<0.001"},{"comp":"OG001","p":"0.027"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":6},"locations":{"siteCount":9,"countries":["United States"]},"refs":{"pmids":["19261295"],"seeAlso":["http://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/022181TOC.cfm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":33},"commonTop":["Headache","Rhinorrhea","Cough","Pharyngolaryngeal Pain","Pyrexia"]}}